Medtronic 2016 Annual Report Download - page 19

Table of Contents
16
Bryan C. Hanson, age 49, has been Executive Vice President and Group President, Minimally Invasive Therapies Group of the
Company since February 2015. Prior to that, he was Senior Vice President and Group President, Covidien since October 2014;
Senior Vice President and Group President, Medical Devices and United States of Covidien from October 2013 to September
2014; Senior Vice President and Group President of Covidien for the Surgical Solutions business from July 2011 to October 2013;
and President of Covidien’s Energy-based Devices business from July 2006 to June 2011. Mr. Hanson held several other positions
of increasing responsibility in sales, marketing and general management with Covidien from October 1992 to July 2006.
Bradley E. Lerman, age 59, has been Senior Vice President, General Counsel and Corporate Secretary of the Company since
January 2015 and of Medtronic, Inc. since May 2014. Prior to that, he was Executive Vice President, General Counsel, and
Corporate Secretary at Federal National Mortgage Association (Fannie Mae) from October 2012 to May 2014; Senior Vice President
and Chief Litigation Counsel at Pfizer, Inc. from January 2009 to September 2012; Partner at Winston & Strawn from August
1998 to January 2009; partner at Kirkland & Ellis from March 1996 to July 1998; Associate Independent Counsel from October
1994 to March 1996; and Assistant U.S. Attorney in the Northern District of Illinois from February 1986 to September 1994.
Geoffrey S. Martha, age 46, has been Executive Vice President and President, Restorative Therapies Group since June 2015. Mr.
Martha previously served as Senior Vice President of Strategy and Business Development of the Company beginning in January
2015 and of Medtronic, Inc. beginning in August 2011. Prior to that, he served as Managing Director of Business Development
at GE Healthcare from April 2007 to July 2011; General Manager for GE Capital Technology Finance Services from November
2003 to March 2007; Senior Vice President, Business Development for GE Capital Vendor Financial Services from February 2002
to October 2003; General Manager for GE Capital Colonial Pacific Leasing from February 2001 to January 2002; and Vice
President, Business Development for Potomac Federal, the GE Capital federal financing investment bank from May 1998 to
January 2001.
Karen L. Parkhill, age 50, joined the Company as Executive Vice President and Chief Financial Officer in June 2016. From 2011
to 2016, Ms. Parkhill served as Vice Chairman and Chief Financial Officer of Comerica Incorporated. Ms. Parkhill was a member
of Comerica’s Management Executive Committee and the Comerica Bank Board of Directors. Prior to joining Comerica, Ms.
Parkhill worked for J.P. Morgan Chase & Co. in various capacities from 1992 to 2011, including serving as Chief Financial Officer
of the Commercial Banking business from 2007 to 2011. Ms. Parkhill is also a current member of the Board of Directors for the
Methodist Health System in Dallas.
Carol A. Surface, age 50, has been Senior Vice President and Chief Human Resources Officer of the Company since January
2015 and of Medtronic, Inc. since September 2013. Prior to that, she was the Executive Vice President and Chief Human Resources
Officer at Best Buy Co., Inc. from March 2010 to September 2013, and held a series of HR leadership roles at PepsiCo Inc., from
May 2000 to March 2010.
Robert ten Hoedt, age 55, has been Executive Vice President and President, EMEA of the Company since January 2015 and of
Medtronic, Inc. since May 2014. Prior to that, he was Senior Vice President and President, EMEA and Canada from 2009 to 2014;
Vice President CardioVascular Europe and Central Asia from 2006 to 2009; Vice President and General Manager, Vitatron from
1999 to 2006; Gastro-Uro leader from 1994 to 1999; and Marketing Manager, Neurological from 1991 to 1994.
Item 1A. Risk Factors
Investing in us involves a variety of risks and uncertainties, known and unknown, including, among others, those discussed below.
Each of the following risks should be carefully considered. Based on the information currently known to us, we believe the
following information identifies the most significant risk factors affecting our Company. However, the risks and uncertainties
described below are not the only ones related to our businesses and are not necessarily listed in the order of their importance.
Additional risks and uncertainty not presently known to us or that we currently believe to be immaterial may also adversely affect
our business.
Risks Relating to the Company
We operate in a highly competitive industry and we may be unable to compete effectively.
We compete in both the therapeutic and diagnostic medical markets in approximately 160 countries throughout the world. These
markets are characterized by rapid change resulting from technological advances and scientific discoveries. In the product lines
in which we compete, we face a mixture of competitors ranging from large manufacturers with multiple business lines to small
manufacturers that offer a limited selection of niche products. Development by other companies of new or improved products,
processes, technologies, or the introduction of reprocessed products or generic versions when our proprietary products lose their
patent protection may make our products or proposed products less competitive. In addition, we face competition from providers
of alternative medical therapies such as pharmaceutical companies.